Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS -- Heat Biologics Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19
Killer T cells are all over the news. Heat will be leader in human health..........stock going to $50
You must be on some medication. This stock will never. Ever be anything but laggard. Might hit $6.00 in 2035
Wow
i hope your right but i dont see it.
HTBX is now going to be bought by major institutions. Everyone knows killer T cells are the only true effective means to fight cancer and the virus.
This stock is going to be pushed to $50 by the big money managers and then forward split. We are going to be experiencing a decade (10 years) of financial success for HTBX. The stock will rise, forward split, rise forward split, and so on.
Lots of good news coming as per the news release. The big money managers will load up all Christmas long, then pow into the new year.
GLTA
Notice of Effectiveness (effect)
Source: Edgar (US Regulatory)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NOTICE OF EFFECTIVENESS
Effective Date: December 11
50.00? That will not and cannot happen. How many RS can this beaten up company survive. Yes bankruptcy. Money will be gone soon. Watch
Gone
FIFTY DOLLARS??
Who are you? Ivan Boesky? L o l
Clay,
Got your notification. We’ll be shorting this into the ground on Monday. Have a good weekend!
HTBX IS A BUY AT THIS MOMENT;
The stock has been moved into the "federal reserve marginable level" which happens to be over $5 per share. Only 22 million shares, $113 million in bank. No need for a reverse, but the company wanted to attract the power of the intuitional investors so they "reversed" the stock into that level.
And most importantly we "have important upcoming milestones related to our programs that we expect to announce soon, which we believe will further validate our strategy."
Stock will be pushed to $50 with the power from the big institutions.
Adding here. Final chance.
Hey Clay, good report for the short cabal....noticed you always show the way forward is to drop, never show the next most imminent move is an uptick. Your short buddies gotta be real proud of you.
Dumb ass, they are doing it to stay on nasdaq - they are about to have a cov19 vac plus other stuff better now then you punk ass short sellers and day traders tanking it. to make 100 bucks. if your to uneducated to say anything smart just go spread your BS someplace else. they have to maintain over 1$ end of story. now go shake some presents under the tree and shut your face! sick of the doom and gloom I didn't get rich In a day people make me sick. and don't use the word educated to spell check me that's another idiot move.
howar
Sure that is going to happen with a 193milion in the bank====
Bankruptcy might be first
this will be the last time i buy into this P.O.S. company. lost on last reverse and sure will lose on this one. holding till the death
R/s was done to open the roads for major institutions to buy in as soon as the company announces the good news.
Stock has to be over $5 for major financial institutions to buy in.
Nice plan in case that was not communicated to shareholders
Look at Greenwich stock. $5 before news, $143 after good news delivered, and the reason that was possible because major institutions were allowed buy in a stock over $5
(HInt: trial results got to be good and we should expect green dollar from the time this message is posted?)
* * $HTBX Video Chart 12-10-2020 * *
Link to Video - click here to watch the technical chart video
Maybe investigate the guy/firm that gave a TP of $4. Did they short big time?
NEWS -- Heat Biologics Provides Business Update
DURHAM, NC / ACCESSWIRE / December 10, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-7. The reverse stock split will take effect as of 12:01 a.m. ET, December 11, 2020. Shares of Heat common stock will trade on a post-split basis on the Nasdaq Capital Market under the existing trading symbol, "HTBX," at the market open on December 11, 2020.
Jeff Wolf, CEO of Heat, commented, "Our sole purpose in conducting this reverse-split was to address market concerns related to the Nasdaq minimum bid price requirement. Importantly, we remain in compliance with Nasdaq requirements and have important upcoming milestones related to our programs that we expect to announce soon, which we believe will further validate our strategy. It's also important to note that we have a solid balance sheet with over $113 million of cash as of December 9, 2020."
During the Company's special shareholder meeting held February 27, 2020, shareholders approved the Company's reverse stock split, and granted the board of directors the authority to implement and determine the exact split ratio, which was set by the board at 1-for-7. Following the reverse stock split, the new CUSIP number will be 42237K 409, with the par value per share of common stock remaining at $0.0002. A proportionate adjustment will be made to the per-share exercise prices and number of shares issuable under all outstanding stock options and warrants.
The reverse stock split is intended to increase the market price per share of the Company's common stock to help ensure a share price high enough to satisfy the $1.00 minimum bid price requirement by Nasdaq and to potentially increase the visibility of our company among a larger pool of institutional investors.
When the reverse stock split becomes effective, every seven shares of the Company's issued and outstanding common stock will be combined into one share of common stock. Effecting the reverse stock split will reduce the number of issued and outstanding common stock from approximately 159.8 million shares to approximately 22.8 million. The reverse stock split will also subsequently adjust outstanding options issued under Heat's equity incentive plan and outstanding warrants to purchase common stock.
No fractional shares will be issued in connection with the reverse stock split. Shareholders of record will receive a cash payment in lieu of fractional shares to which they would otherwise be entitled. Shareholders with shares held in certificate form will receive a Letter of Transmittal with instructions from Heat's transfer and exchange agent, Continental Stock Transfer & Trust Company. Shareholders that hold shares in book-entry form or in brokerage accounts are not required to take any action, and will see the impact of the reverse stock split reflected in their accounts. Additionally, beneficial holders may contact their bank, broker, custodian or other nominee with questions regarding processing procedures for the reverse stock split. Additional information is available in the Form 8-K filed today with the U.S. Securities and Exchange Commission, and in the definitive proxy statement filed on January 24, 2020.
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The Company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on Heat's current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding important upcoming milestones related to Heat's programs that will further validate its strategy and Heat's ability to realize any anticipated benefits from the reverse stock split, including maintaining its listing on the Nasdaq Capital Market and attracting new investors. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
SOURCE: Heat Biologics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/620359/Heat-Biologics-Provides-Business-Update
Post split He will bleed this back to 1.00 within days imo
“The reverse stock split is intended to increase the market price per share to help ensure a share price high enough to satisfy the $1.00 minimum bid price requirement by Nasdaq. However, there is no assurance that the reverse stock split will have the desired effect of sufficiently increasing the bid price of the Company’s common stock for the required period.”
They fucked everyone
On top of that they registered more shares
Tis the Season To F... the Shareholders
A lot of us here waiting
What we waiting on here? Looks ready to pop. You guys still like it?
that was for the scam guy lol
Enough consolidation to make a run soon ..
So when is the NYSE going to kick this scam off the Nasdaq down to the lowly OTC?
Making the big move above $1.17 and off to the $2s with little resistance
lots of big buys going on right now
imo this will take off later today ahead of results
No worries. HS-100 trial result is due any day and it should be good. T-cell is the way to go
PPS will bounce back up
Glta $$
there gonna have to pump it up at some point
Followers
|
155
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6042
|
Created
|
01/26/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |